Determining the value of drug development candidates and technology platforms

Abstract

This paper explains a comprehensive and systematic approach to evaluate drug development projects and technology platforms, using an augmented version of net present value (NPV). The benefits of financial models for value-driven project and portfolio management, licensing negotiations and investors' decisions are discussed.